Befejeződött1/2. fázis
A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
Key facts
- Where
- Bergamo, Bologna, Florence, Orbassano és Perugia, OlaszországSee the 5 sites
- Phase
- 1/2. fázis
Where in Olaszország
- Azienda Socio Sanitaria Territoriale Papa Giovanni XXIIIBergamo, OlaszországNo longer taking part
- Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere ScientificoBologna, OlaszországNo longer taking part
- Careggi University HospitalFlorence, OlaszországNo longer taking part
- Azienda Ospedaliero-Universitaria San Luigi GonzagaOrbassano, OlaszországNo longer taking part
- Hospital Santa Maria Della MisericordiaPerugia, OlaszországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Incyte Corp.
- Trial code
- EU 2023-503624-83-00
- Record updated
- 2026. március 19.